Clinical Trials · NCT00938717

Trial of Linaclotide in Patients With Irritable Bowel Syndrome With Constipation (IBS-C)

CompletedPhase 3Linaclotide (Approved)
Phase
Phase 3
Recruitment status
Completed
Sponsor
Ironwood Pharmaceuticals, Inc.
Enrollment
805
Start date
Jul 2009
Locations
107 sites, United States
Primary endpoint
Abdominal Pain and Complete Spontaneous Bowel Movement (APC) Responder, 9 Out of 12 Weeks
View Linaclotide compound reference